93 related articles for article (PubMed ID: 2428937)
1. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
Jenner P; Taquet H; Mauborgne A; Benoliel JT; Cesselin F; Rose S; Javoy-Agid F; Agid Y; Marsden CD
J Neurochem; 1986 Nov; 47(5):1548-51. PubMed ID: 2428937
[TBL] [Abstract][Full Text] [Related]
2. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
[TBL] [Abstract][Full Text] [Related]
3. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel JJ; Marsden CD; Legrand JC; Agid Y
Neuropeptides; 1988 Oct; 12(3):105-10. PubMed ID: 2468106
[TBL] [Abstract][Full Text] [Related]
4. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
5. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
[TBL] [Abstract][Full Text] [Related]
6. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset.
Pérez-Otaño I; Herrero MT; Luquin MR; Obeso JA; Del Río J
Brain Res; 1992 Jul; 585(1-2):156-60. PubMed ID: 1380867
[TBL] [Abstract][Full Text] [Related]
7. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
[TBL] [Abstract][Full Text] [Related]
8. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Eur J Pharmacol; 1990 May; 181(1-2):97-103. PubMed ID: 2117541
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Jolkkonen J; Jenner P; Marsden CD
Brain Res Mol Brain Res; 1995 Sep; 32(2):297-307. PubMed ID: 7500841
[TBL] [Abstract][Full Text] [Related]
10. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden CD
Neurosci Lett; 1989 Jul; 101(3):305-10. PubMed ID: 2505199
[TBL] [Abstract][Full Text] [Related]
11. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.
Irwin I; DeLanney LE; Forno LS; Finnegan KT; Di Monte DA; Langston JW
Brain Res; 1990 Oct; 531(1-2):242-52. PubMed ID: 1981162
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Pérez-Otaño I; Luquin MR; Oset C; Herrero MT; Kupsch A; Oertel W; Obeso JA; Del Río J
Exp Neurol; 1995 Jan; 131(1):108-13. PubMed ID: 7534717
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
[TBL] [Abstract][Full Text] [Related]
14. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Ueki A; Chong PN; Albanese A; Rose S; Chivers JK; Jenner P; Marsden CD
Neuropharmacology; 1989 Oct; 28(10):1089-97. PubMed ID: 2510050
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Sirinathsinghji DJ; Whittington PE; Audsley AR
Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361
[TBL] [Abstract][Full Text] [Related]
16. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Irifune M; Fukuzaki K; Fukuda T
Neurosci Lett; 1994 Aug; 178(1):95-8. PubMed ID: 7816348
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
19. Administration of MPTP to the common marmoset does not alter cortical cholinergic function.
Garvey J; Petersen M; Waters CM; Rose SP; Hunt S; Briggs R; Jenner P; Marsden CD
Mov Disord; 1986; 1(2):129-34. PubMed ID: 3143064
[TBL] [Abstract][Full Text] [Related]
20. [Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Chen S
Zhonghua Yi Xue Za Zhi; 1990 May; 70(5):252-4, 18. PubMed ID: 2168792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
